Sales -7%, adj. EBIT -2.7m vs. ABGSCe Gross margin at record high level 48% (45%) Performance Chemic...
Q1 sales 3% below our ests. at SEK 207m, for -2.3% org.
Redeye gives its initial take on BONESUPPORT’s Q1 report.
Redeye comments on Fortnox’s Q1, with the key figures matching our expectations.
Redeye comments on Waystream’s Q1 report, which managed to beat our estimates across the board.
Redeye comments on Polygiene Group´s Q1 2025. Polygiene Group delivered positive growth of 18% YoY w...
Enea's net sales rose 7% to SEK214m, beating Redeye Research Estimate (RRe) by 2%, with the network ...
Redeye comments on Lime’s Q1 report, with key figures missing our forecasts slightly.
Sales -3% vs. cons, adj. EBITA +21% vs. cons Announces growth initiatives & cost savings efforts Con...
Redeye updates its outlook on Nanologica, continuing to anticipate a considerable sales ramp-up in H...
Redeye initiates coverage of Camurus, a biotech company that made it from start-up to large cap, cur...
Redeye updates its estimates and valuation following Vitec releasing its Q1 2025 report.
Report out 8 May at 08:00 CEST Q1e: sales of SEK 52m +37% y-o-y, adj.
We raise '25e-'27e adj. EBITA by 10-1% on higher margins Low renegotiation risk 2025 and growth upsi...
Redeye is not entirely surprised to see that Absolent has experienced significant headwinds in Q1.
Hifab Group AB (”Hifab”, ”Koncernen” eller ”Bolaget”) publicerade den 23 april 2025 Bolagets delårsr...
Luxbright AB (”Luxbright” eller ”Bolaget”) meddelade den 22 april 2025 att Bolaget, villkorat av bol...
Volvo delivered a mixed report, with EBIT 12% below Infront consensus.
Adj. EBITA +12% vs. cons, +39% vs. ABGSCe Better margins and guidance to improve conviction in margi...
Q1 report Tuesday, 29 April at 08:30 CET '25e EBITA up 2% 10-5x EBITA in '25e-'27e, 16-19% FCF yield...